|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/4184 | (2006.01) |
| A61K 31/506 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 31/5377 | (2006.01) |
| (11) | Patento numeris | 3125885 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15715805.6 |
| Europos patento paraiškos padavimo data | 2015-04-02 | |
| (97) | Europos patento paraiškos paskelbimo data | 2017-02-08 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-06-30 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/GB2015/051042 |
| Data | 2015-04-02 |
| (87) | Numeris | WO 2015/150826 |
| Data | 2015-10-08 |
| (30) | Numeris | Data | Šalis |
| 201461975088 P | 2014-04-04 | US | |
| 201462013573 P | 2014-06-18 | US |
| (72) |
CROSS, Darren Anthony Edward , GB
EBERLEIN, Catherine Anne , GB
|
| (73) |
Astrazeneca AB ,
151 85 Södertälje,
SE
|
| (54) | COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER |
| COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER |